Berenberg Starts Cue Biopharma (CUE) at Buy

November 24, 2020 6:34 AM EST
Get Alerts CUE Hot Sheet
Price: $15.08 --0%

Rating Summary:
    7 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 10 | Down: 12 | New: 29
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Berenberg analyst Zhiqiang Shu initiates coverage on Cue Biopharma (NASDAQ: CUE) with a Buy rating and a price target of $30.00.

The analyst commented, "Cue Biopharma is developing a highly selective IL-2-based cancer therapy to treat head and neck cancer. We think potential approval opportunities (we assume 30%) for this drug in both advanced disease and front-line settings are under-appreciated by the market. Based on a favourable risk/reward profile, we believe the current valuation is an attractive entry point. We initiate with a Buy rating."

For an analyst ratings summary and ratings history on Cue Biopharma click here. For more ratings news on Cue Biopharma click here.

Shares of Cue Biopharma closed at $12.01 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, New Coverage